Editing AUA: Overactive Bladder (2019) (section)

==== OnabotulinumtoxinA ====
* '''<span style="color:#ff0000">Intradetrusor onabotulinumtoxinA (100U) may be offered as third-line treatment in the carefully-selected and thoroughly-counseled patient who has been refractory to first- and second-line OAB treatments.</span>'''
**'''<span style="color:#ff0000">Considered a treatment STANDARD in patients with moderate to severe OAB symptoms</span>'''
*'''<span style="color:#ff0000">Dosing: FDA-approved dose of 200U for neurogenic OAB</span>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649594/ §][https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739988/ §]'''
**'''<span style="color:#ff0000">Not FDA-approved in non-neurogenic OAB patients, 100U typically used</span>'''
*'''<span style="color:#ff0000">Adverse events</span>'''
*#'''<span style="color:#ff0000">Urinary retention</span>'''
*#*<span style="color:#ff0000">'''The patient must be able and willing to return for frequent post-void residual evaluation and able and willing to perform self-catheterization if necessary.'''
*#'''<span style="color:#ff0000">Gross hematuria</span>''' 
*#'''<span style="color:#ff0000">UTI</span>'''
*#'''<span style="color:#ff0000">Dry mouth</span>'''
*#'''<span style="color:#ff0000">Dysphagia</span>'''
*#'''<span style="color:#ff0000">Impaired vision</span>'''
*#'''<span style="color:#ff0000">Eyelid weakness</span>'''
*#'''<span style="color:#ff0000">Arm weakness</span>'''
*#'''<span style="color:#ff0000">Leg weakness</span>'''
*#'''<span style="color:#ff0000">Torso weakness</span>'''
*'''Technique'''
**'''A randomized trial comparing trigone-including  versus trigone-sparing injections of abobotulinumtoxinA found greater symptom improvement in the trigone-including injected group'''
*'''<span style="color:#ff0000">Effects diminish over time for most patients; therefore, patients also should be informed that repeat injections are likely to be necessary to maintain symptom reduction</span>'''